Chimeric Therapeutics Limited · ASX:CHM
Chimeric Therapeutics — Shareholder Meeting (November 2024)
15 slides from Chimeric Therapeutics's shareholder meeting presentation, Nov 12, 2024
Slide 1: AGM Presentation and CEO Appointment
ASX ANNOUNCEMENT 12 November 2024 AGM Presentation and CEO Appointment Sydney, Australia, 12 November 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide the presentation to delivered at the Annual General Meeting to be held
Slide 2: ASX announcement continued and contacts
solid tumours. CLTX CAR T is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023. CHM CORE-NK is a potentially best-in-class, clinically va
Slide 3: Chimeric Therapeutics Investor Update 2024
CHIMERIC CHIMERIC THERAPEUTICS PIONEERS IN CELL THERAPY Investor Update | 2024 ASX: CHM 20 24 CHIMERICTHERAPEUTICS.COM
Slide 4: Disclaimer
NOV 2024 | 2 DISCLAIMER Certain statements contained in this presentation, applicable regulatory authorities may ask for additional including, without limitation, statements containing the data, information or studies to be completed or provided words “believes,” “plans,” “expects,” “anticipates,” a
Slide 5: Dr Rebecca McQualter Appointed Chief Executive Officer
NOV 2024 | 3 Dr Rebecca McQualter Appointed Chief Executive Officer The Company is pleased to announce the appointment of current Chief Operating Officer, Dr Rebecca McQualter as Chief Executive CHIMERIC THERAPEUTICS Officer effective from 12 Nov 2024 For the purpose of ASX Listing Rule 3.16.4 Total
Slide 6: Chimeric Therapeutics
CHIMERIC CHIMERIC THERAPEUTICS PIONEERS IN CELL THERAPY Investor Update | 2024 ASX: CHM 20 24 CHIMERICTHERAPEUTICS.COM
Slide 7: CHM is a cancer cell therapy company
NOV 2024 | 5 ASX:CHM CHIMERIC THERAPEUTICS CHM is a cancer cell therapy company with 3 CAR T & NK cell assets in 4 Phase 1/1b clinical trials CHIMERICTHERAPEUTICS.COM
Slide 8: CAR-T Cell Therapy Explained
NOV 2024 | 6 CAR-T CELL THERAPY EXPLAINED Use a patients own blood cells to make their individualised cancer therapy CHIMERIC THERAPEUTICS Laboratory Individual therapy engineering manufactured Leukapheresis (blood draw) Infusion into from individual patient individual patient Cell Therapy has been
Slide 9: Broad Portfolio: Novel cell therapies; Clinical Trials
NOV 2024 | 7 CHM: BROAD PORTFOLIO 3 Novel cell therapies; 4 Clinical Trials CHM CDH17 CHM CLTX CHM CORE-NK CHIMERIC THERAPEUTICS CAR-T CAR-T ‘OFF THE SHELF’ NK Technology from: Technology from: Technology from: Phase 1A completed: COH PHASE 1B PHASE 1B PHASE 1/2 TRIAL OPEN PHASE 1B TRIAL OPEN TRIAL
Slide 10: CHM CORE NK + SOC
NOV 2024 | 8 CHM CORE NK + SOC Ongoing Complete response in high risk blood cancer 48 months durability COMPLETE PATIENT #8 RESPONSE 33-year-old female CORE NK INFUSION CHIMERIC THERAPEUTICS DAY 100 SITE: MDACC Enabling patient to Patient Doses undergo transplant DIAGNOSIS: Myeloid Dysplastic Syndro
Slide 11: CHM CORE NK Combination Trial
NOV 2024 | 9 CHM CORE NK COMBINATION TRIAL Complete response in high risk blood cancer combination trial PATIENT #3 female CORE NK INFUSION + TGF-B CHIMERIC THERAPEUTICS SITE: Case Western Day 1 DIAGNOSIS: Actue Myeloid Dysplastic Syndrome SAFETY: No dose limiting toxicities, no cytokine COMPLETE re
Slide 12: Multiple Clinical Catalysts in the Next 12 Months
NOV 2024 | 10 MULTIPLE CLINICAL CATALYSTS IN THE NEXT 12MTHS 2023 Achievements and Deliverables in 2024 2023 Achievements 2024 Deliverables ✓ Ph. 1/2 Site Open CHM CDH17 ✓ FDA IND Clearance for Ph. 1/2 Trial ✓ 1st patient dosed CHIMERIC THERAPEUTICS CHM 2101 • 1st dose co-hort complete ✓ Ph. 1A trai
Slide 13: CHM Leadership Team
NOV 2024 | 11 CHM LEADERSHIP TEAM EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALISATION CHIMERIC THERAPEUTICS Dr Rebecca McQUALTER Dr Jason LITTEN Dr Stephanie ASTROW Mr Kelly THORNBURG Chief Executive Officer Chief Medical Officer Chief Scientific Officer VP Manufacturing 75+ 50+ 5/6 EXPERIENCE E
Slide 14: Investment Highlights
NOV 2024 | 12 INVESTMENT HIGHLIGHTS 4 4 Phase 1 clinical trials under 3 FDA INDs at 4 leading US centres CORPORATE PROFILE Multiple clinical updates ASX: CHM CHIMERIC THERAPEUTICS in the next 12mths Exchange Share Price $0.01 Experienced leadership team in cell therapy clinical development 52 Week R
Slide 15: Chimeric Therapeutics
CHIMERIC CHIMERIC THERAPEUTICS PIONEERS IN CELL THERAPY Dr Rebecca McQualter Chief Executive Officer Chimeric Therapeutics Ltd Melbourne, Australia Tel: +61 498 966 180 investors@chimerictherapeutics.com 20 24 CHIMERICTHERAPEUTICS.COM
Chimeric Therapeutics — Shareholder Meeting (November 2024) on 6ix